| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash used in investing activities | -29 | 50,731 |
| Proceeds from issuance of common stock, net of issuance costs | 167,973 | - |
| Proceeds from the exercise of stock options | 418 | 369 |
| Payment of deferred financing costs | 53 | 353 |
| Proceeds from issuance of common stock in an initial public offering and atm facility, net of issuance costs | - | 81,857 |
| Net cash provided by financing activities | 168,338 | 81,873 |
| Net increase in cash and cash equivalents | 38,379 | 38,472 |
| Cash and cash equivalents at beginning of period | 74,293 | - |
| Cash and cash equivalents at end of period | 112,672 | - |
ArriVent BioPharma, Inc. (AVBP)
ArriVent BioPharma, Inc. (AVBP)